| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 25 | 37.2x | 17.8x | Bottom tier | |
Growth | 51 | 6.7% | 7.1% | Around median | |
Quality | 38 | 7.5% | 4.5% | Bottom tier | |
Safety | 66 | 1.4x | 2.6x | Top tier | |
Capital Return | 24 | 0.30% | 2.12% | Bottom tier | |
Momentum | 64 | -8.6% | 2.9% | Around median | |
Sentiment | 46 | 7 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Stevanato Group serves pharmaceutical and biotechnology companies through two interconnected segments. The Biopharmaceutical and Diagnostic Solutions segment, BDS, provides containment and delivery systems for injectable drugs, including Nexa and Alba syringes, EZ-fill ready-to-fill vials, cartridges, and the Alina and Deora pen platforms, while the Engineering segment sells visual inspection and glass converting equipment, assembly lines, and after-sales services. The company's strategy is to increase the share of high-value solutions and integrate glass packaging with drug delivery devices, particularly for biologic applications and GLP-1 therapies.
In Q2 fiscal 2026, revenue rose 8% year over year to €302 million. The BDS segment grew 9% to €266.2 million, compared with a 2% decline in Engineering revenue to €35.8 million; BDS therefore accounted for approximately 88% of group revenue. High-value solutions revenue rose 16% to €135.9 million, or 45% of total revenue, supported by Nexa and Alba syringes and EZ-fill vials, while revenue related to GLP therapies represented approximately 22% to 23% of the total.
Gross profit margin reached 28.7% in Q2 fiscal 2026, up 60 basis points, and adjusted operating margin rose 250 basis points to 18%, while adjusted earnings before interest, taxes, depreciation, and amortization increased 21% to €78.7 million at a margin of 26%. By contrast, €12.2 million in expenses related to the sale of Balda C. Brewer and higher taxes resulted in reported net profit of €23 million and diluted earnings per share of €0.08, while adjusted net profit rose 20% to €37.6 million and adjusted earnings per share increased to €0.14. On an annual basis, fiscal 2025 revenue rose to $1.2 billion and net income to $139.8 million, compared with $1.1 billion and $117.8 million in fiscal 2024.
Automated analysis for informational purposes only — not investment advice.
Analyst consensus rates STVN as a “Buy,” with an average price target of $32; however, both the highest and lowest targets are $32, meaning the range provides no useful dispersion for measuring differences in opinion. This target is above the 52-week range high of $28, compared with a low of $12.89, but the absence of an available price-to-earnings ratio and the recording of negative free cash flow of €32 million in Q2 fiscal 2026 make the stock's valuation heavily dependent on achieving growth in high-value solutions and successfully ramping up the new facilities.
Figures in the text are as of 2026-08-30; the live price is shown at the top of the page.
Stevanato Group's revenue rose 8% to €302 million in Q2 fiscal 2026. The BDS segment led growth with a 9% increase to €266.2 million, while Engineering revenue declined 2% to €35.8 million. High-value solutions were the fastest-growing driver, rising 16% to €135.9 million with support from Nexa and Alba syringes and EZ-fill vials. Revenue from biologic applications also increased 30% during the quarter.
Alina is a variable-dose pen owned by Stevanato and integrated with the company's cartridges into a single system. By the August 4, 2026 call, a liraglutide-based therapy using two versions of Alina had received approvals in several European countries for diabetes and weight-management applications. Management included Alina revenue in its fiscal 2026 guidance and said the platform is positioned to achieve double-digit growth in subsequent years. The company is investing in its German facility to increase industrial capacity dedicated to the product over 12 to 36 months beginning in August 2026.
Revenue related to GLP therapies represented approximately 22%–23% of total Q2 fiscal 2026 revenue. Management stated that biologic applications had grown to represent approximately 42% of BDS revenue, compared with slightly less than 20% in 2022. Stevanato serves two leading GLP-1 therapy developers and also works with biosimilar programs using Nexa, ready-to-fill cartridges, and Alina. Biologics revenue grew 6% in the first half of fiscal 2026, with several customer programs remaining in phases 2 and 3 of clinical development.
The company expects revenue of between €1.260 billion and €1.280 billion in fiscal 2026, after accounting for an approximately €15 million reduction associated with the sale of Balda C. Brewer. Adjusted earnings before interest, taxes, depreciation, and amortization guidance ranges from €335 million to €345.2 million, and adjusted diluted earnings per share from €0.60 to €0.62. Management expects high-single-digit growth for BDS and a mid-single-digit to low-double-digit decline for Engineering. It also targets high-value solutions equal to 47%–48% of revenue and free cash flow of between breakeven and €20 million.
The company ended Q2 fiscal 2026 with net debt of €360.3 million and recorded negative free cash flow of €32 million. Capital expenditure was €52 million, while payments for property, plant, and equipment and intangible assets reached €65.7 million as investment in Fishers, Latina, and Alina continued. Engineering also faces longer sales cycles and guidance for declining revenue during fiscal 2026. In addition, €12.2 million in expenses related to the sale of Balda C. Brewer and higher taxes weighed on reported net profit in the quarter.
Net income was $145.7 million and earnings per share were 0.55 in fiscal 2023, then declined to $117.8 million and 0.43 in fiscal 2024. In fiscal 2025, net income recovered to $139.8 million and earnings per share to 0.51, but both remained below fiscal 2023 levels. Over the same period, revenue was $1.1 billion in both fiscal 2023 and fiscal 2024 before rising to $1.2 billion in fiscal 2025.
